Table 1.
Baseline patient demographics
| NACRT | NACRT + AC | Total | P-value | ||||
| N | (%) | N | (%) | N | (%) | ||
| Age, years | |||||||
| Mean (SD) | 61.9 (9.3) | 58.5 (9.0) | 61.7 (9.3) | 0.000 | |||
| Sex | 0.001 | ||||||
| Male | 5311 | (84) | 416 | (90) | 5727 | (84) | |
| Female | 1011 | (16) | 47 | (10) | 1058 | (16) | |
| Total | 6322 | (100) | 463 | (100) | 6785 | (100) | |
| Charlson Comorbidity Score | 0.407 | ||||||
| 0 | 4690 | (74) | 353 | (76) | 5043 | (74) | |
| 1 | 1336 | (21) | 94 | (20) | 1430 | (21) | |
| ≥ 2 | 296 | (5) | 16 | (3) | 312 | (5) | |
| Total | 6322 | (100) | 463 | (100) | 6785 | (100) | |
| Histology | 0.000 | ||||||
| Adenocarcinoma | 5184 | (83) | 421 | (91) | 5605 | (83) | |
| SCC | 1068 | (17) | 40 | (9) | 1108 | (17) | |
| Total | 6252 | (100) | 461 | (100) | 6713 | (100) | |
| Grade | 0.010 | ||||||
| Well-Differentiated | 289 | (5) | 14 | (3) | 303 | (5) | |
| Moderately-Differentiated | 2376 | (44) | 159 | (38) | 2535 | (43) | |
| Poorly-Differentiated | 2695 | (49) | 238 | (57) | 2933 | (50) | |
| Undifferentiated | 94 | (2) | 4 | (1) | 98 | (2) | |
| Total | 5454 | (100) | 415 | (100) | 5869 | (100) | |
| LVSI | 0.038 | ||||||
| Negative | 2051 | (32) | 133 | (29) | 2184 | (32) | |
| Positive | 406 | (6) | 42 | (9) | 448 | (7) | |
| Unknown | 3865 | (61) | 288 | (62) | 4153 | (61) | |
| Total | 6322 | (100) | 463 | (100) | 6785 | (100) | |
| Clinical T-Stage | 0.531 | ||||||
| T0 | 5 | (0) | 0 | (0) | 5 | (0) | |
| T1 | 331 | (6) | 19 | (5) | 350 | (6) | |
| T2 | 1168 | (20) | 80 | (19) | 1248 | (20) | |
| T3 | 4077 | (71) | 311 | (74) | 4388 | (71) | |
| T4 | 170 | (3) | 9 | (2) | 179 | (3) | |
| Total | 5751 | (100) | 419 | (100) | 6170 | (100) | |
| Clinical N-Stage | 0.017 | ||||||
| N0 | 2264 | (38) | 138 | (31) | 2402 | (38) | |
| N1 | 3174 | (53) | 265 | (60) | 3439 | (54) | |
| N2 | 450 | (8) | 30 | (7) | 480 | (8) | |
| N3 | 59 | (1) | 7 | (2) | 66 | (1) | |
| Total | 5947 | (100) | 440 | (100) | 6387 | (100) | |
| Pathologic T-Stage | 0.000 | ||||||
| ypT0 | 1021 | (21) | 49 | (12) | 1070 | (20) | |
| ypT1 | 924 | (19) | 51 | (13) | 975 | (19) | |
| ypT2 | 962 | (20) | 89 | (22) | 1051 | (20) | |
| ypT3 | 1897 | (39) | 212 | (53) | 2109 | (40) | |
| ypT4 | 57 | (1) | 1 | (0) | 58 | (1) | |
| Total | 4861 | (100) | 402 | (100) | 5263 | (100) | |
| Pathologic N-Stage | 0.000 | ||||||
| ypN0 | 3309 | (65) | 123 | (30) | 3432 | (63) | |
| ypN1 | 1345 | (27) | 205 | (50) | 1550 | (28) | |
| ypN2 | 316 | (6) | 54 | (13) | 370 | (7) | |
| ypN3 | 94 | (2) | 31 | (8) | 125 | (2) | |
| Total | 5064 | (100) | 413 | (100) | 5477 | (100) | |
| Surgery Type | 0.032 | ||||||
| Partial Esophagectomy | 949 | (15) | 57 | (12) | 1006 | (15) | |
| Total Esophagectomy | 646 | (10) | 48 | (10) | 694 | (10) | |
| Esophagectomy & Laryngectomy or Gastrectomy | 4294 | (68) | 339 | (73) | 4633 | (68) | |
| Esophagectomy, NOS | 433 | (7) | 19 | (4) | 452 | (7) | |
| Total | 6322 | (100) | 463 | (100) | 6785 | (100) | |
| Margin Status | 0.001 | ||||||
| Negative Margins | 5765 | (97) | 411 | (94) | 6176 | (97) | |
| Positive Margins | 186 | (3) | 27 | (6) | 213 | (3) | |
| Total | 5951 | (100) | 438 | (100) | 6389 | (100) | |
| Radiation Dose, Gy | 0.012 | ||||||
| Median (IQR) | 50.40 (46.80 – 50.40) | 50.40 (45.00 – 50.40) | 50.40 (46.00 – 50.40) | ||||
AC, adjuvant chemotherapy; Gy, Gray; IQR, interquartile range; LVSI, lymphovascular space invasion; NACRT, neoadjuvant chemoradiotherapy; No., number; NOS, not otherwise specified; SCC, squamous cell carcinoma; SD, standard deviation.